Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26

Abstract The skyrocketing cost of health‐care demands that we question when to use multigene assay testing in the planning of treatment for breast cancer patients. A previously published algorithmic model gave recommendations for which cases to send out for Oncotype DX® (ODX) testing. This study is...

Description complète

Détails bibliographiques

Auteurs principaux:	Bradley M. Turner, Mary Ann Gimenez‐Sanders, Armen Soukiazian, Andrea C. Breaux, Kristin Skinner, Michelle Shayne, Nyrie Soukiazian, Marilyn Ling, David G. Hicks
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2019-08-01
Collection:	Cancer Medicine
Sujets:	algorithm ER+ breast cancer Oncotype DX® recurrence RoMMa
Accès en ligne:	https://doi.org/10.1002/cam4.2323
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!